Chief Executive Officer Of Aurinia Pharmaceuticals Makes $12.46M Buy

On June 3, KEVIN TANG, Chief Executive Officer at Aurinia Pharmaceuticals (NASDAQ:AUPH) executed a significant insider buy, as disclosed in the latest SEC filing.

What Happened: TANG made a significant move by purchasing 814,606 shares of Aurinia Pharmaceuticals as reported in a Form 4 filing with the U.S. Securities and Exchange Commission. The transaction's total worth stands at $12,455,227.

The latest update on Wednesday morning shows Aurinia Pharmaceuticals shares up by 2.47%, trading at $15.98.

Discovering Aurinia Pharmaceuticals: A Closer Look

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Financial Insights: Aurinia Pharmaceuticals

Revenue Growth: Over the 3 months period, Aurinia Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 24.4% as of 31 March, 2026. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.

Insights into Profitability:

• Gross Margin: The company excels with a remarkable gross margin of 91.63%, indicating superior cost efficiency and profitability compared to its industry peers.
• Earnings per Share (EPS): The company excels with an EPS that surpasses the industry average. With a current EPS of 0.26, Aurinia Pharmaceuticals showcases strong earnings per share.

Debt Management: Aurinia Pharmaceuticals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.12.

Financial Valuation Breakdown:

• Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 7.12 is lower than the industry average, indicating potential undervaluation for the stock.
• Price to Sales (P/S) Ratio: The current P/S ratio of 7.08 is above industry norms, reflecting an elevated valuation for Aurinia Pharmaceuticals's stock and potential overvaluation based on sales performance.
• EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): Aurinia Pharmaceuticals's EV/EBITDA ratio at 10.6 suggests potential undervaluation, falling below industry averages.

Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.

The Importance of Insider Transactions

Insider transactions contribute to decision-making but should be supplemented by a comprehensive investment analysis.

From a legal standpoint, the term "insider" pertains to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.

A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock.

While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.

A Closer Look at Important Transaction Codes

For investors, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.

Check Out The Full List Of Aurinia Pharmaceuticals's Insider Trades.

This article was generated by Benzinga's automated content engine and reviewed by an editor.